启明、弘晖押注，89岁医药泰斗创业5年冲刺IPO！

Core Insights - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, marking its ambition to enter the public market after five years of rapid development [1][40] - The company has successfully completed seven rounds of financing, raising a total of 521.5 million RMB, with a post-investment valuation exceeding 2 billion RMB following its Series C round in May 2025 [1][32] - The core product, LP-003, is an anti-IgE monoclonal antibody that aims to compete directly with the established drug omalizumab, which is projected to generate over 4.4 billion USD (approximately 310 billion RMB) in global sales in 2024 [1][43][44] Financing Overview - Tianchen Biopharmaceuticals has completed seven financing rounds since its establishment in October 2020, with the most recent Series C round raising 207.8 million RMB [2][32] - The financing rounds have included participation from notable investors such as Dongfang Fuhai, Qiming Venture Partners, and Honghui Fund [2][32] - The company’s valuation has seen significant growth, from 398.5 million RMB in its Series A round to over 2 billion RMB in its Series C round [2][32] Product Development - The lead product, LP-003, is designed to outperform omalizumab in terms of affinity, efficacy, and dosing frequency [3][44] - Clinical data indicates that LP-003 has a binding affinity of 2.08 pM, which is 860 times higher than that of omalizumab [13][14] - LP-003 has demonstrated faster onset of action and longer half-life, with a half-life of 45 to 76 days compared to omalizumab's 20 days, potentially allowing for quarterly dosing instead of bi-weekly or monthly [18][19][20] Market Potential - The global market for allergy treatments is projected to reach 68.8 billion USD in 2024, with significant growth expected in the Chinese market, which is anticipated to reach 22.9 billion USD by 2030 [33] - The increasing prevalence of allergic diseases, affecting approximately 40% of the global population, presents a substantial market opportunity for LP-003 [33] - The company aims to leverage its innovative product to capture market share in a competitive landscape that includes both established drugs and emerging biosimilars [34][35] Financial Strategy - Tianchen Biopharmaceuticals has maintained a high R&D expenditure, with R&D costs constituting 79% to 92% of total operating expenses, reflecting a focused investment strategy [25][26] - The company has not generated any revenue yet, but its financial structure is designed to support ongoing clinical trials and future commercialization efforts [25][30] - The decision to outsource production to CDMO partners rather than building in-house manufacturing capabilities is aimed at minimizing capital expenditure and maximizing R&D efficiency [29][30]